Based on the key measurements obtained from Benitec Biopharma's financial statements, Benitec Biopharma Ltd is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December. At present, Benitec Biopharma's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 5.2 M, whereas Net Debt is projected to grow to (48.1 M). Key indicators impacting Benitec Biopharma's financial strength include:
Investors should never underestimate Benitec Biopharma's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Benitec Biopharma's cash flow, debt, and profitability to make informed and accurate decisions about investing in Benitec Biopharma Ltd.
Net Income
(20.66 Million)
Benitec
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change In Cash
Free Cash Flow
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Liabilities
Sale Purchase Of Stock
Change In Working Capital
Depreciation
Change To Operating Activities
Other Cashflows From Investing Activities
Change To Netincome
Change To Inventory
Investments
Stock Based Compensation
Issuance Of Capital Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Common Stock
Property Plant Equipment
Net Tangible Assets
Non Currrent Assets Other
Other Assets
Short Term Investments
Non Current Liabilities Total
Capital Lease Obligations
Short Term Debt
Short Long Term Debt Total
Net Invested Capital
Net Working Capital
Depreciation And Amortization
Interest Expense
Selling General Administrative
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Net Income From Continuing Ops
Net Income Applicable To Common Shares
Interest Income
Reconciled Depreciation
Net Interest Income
Probability Of Bankruptcy
Understanding current and past Benitec Biopharma Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Benitec Biopharma's financial statements are interrelated, with each one affecting the others. For example, an increase in Benitec Biopharma's assets may result in an increase in income on the income statement.
Please note, the presentation of Benitec Biopharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Benitec Biopharma's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Benitec Biopharma's management manipulating its earnings.
Benitec Biopharma Stock Summary
Benitec Biopharma competes with Bio Path, Capricor Therapeutics, NextCure, Aileron Therapeutics, and Zura Bio. Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company was incorporated in 1995 and is headquartered in Hayward, California. Benitec Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 18 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Benitec Biopharma's current stock value. Our valuation model uses many indicators to compare Benitec Biopharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Benitec Biopharma competition to find correlations between indicators driving Benitec Biopharma's intrinsic value. More Info.
Benitec Biopharma Ltd is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Benitec Biopharma's Return On Equity is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Benitec Biopharma's earnings, one of the primary drivers of an investment's value.
Benitec Biopharma Systematic Risk
Benitec Biopharma's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Benitec Biopharma volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Benitec Biopharma correlated with the market. If Beta is less than 0 Benitec Biopharma generally moves in the opposite direction as compared to the market. If Benitec Biopharma Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Benitec Biopharma is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Benitec Biopharma is generally in the same direction as the market. If Beta > 1 Benitec Biopharma moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Benitec Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Benitec Biopharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Benitec Biopharma growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.0208
At present, Benitec Biopharma's Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.
Benitec Biopharma November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Benitec Biopharma help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Benitec Biopharma Ltd. We use our internally-developed statistical techniques to arrive at the intrinsic value of Benitec Biopharma Ltd based on widely used predictive technical indicators. In general, we focus on analyzing Benitec Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Benitec Biopharma's daily price indicators and compare them against related drivers.
When running Benitec Biopharma's price analysis, check to measure Benitec Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Benitec Biopharma is operating at the current time. Most of Benitec Biopharma's value examination focuses on studying past and present price action to predict the probability of Benitec Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Benitec Biopharma's price. Additionally, you may evaluate how the addition of Benitec Biopharma to your portfolios can decrease your overall portfolio volatility.